Charles Ayemoba was previously a Pre-Doctoral Trainee of Biomedical Research Technologies at Boston University School of Medicine. He is now a Staff Research Associate at the University of California, San Francisco. Charles graduated from the University of Illinois at Urbana-Champaign with a bachelors degree in Molecular and Cellular Biology, and then went on to attend Boston University School of Medicine and received a Masters in Biotechnology.
Pre-Doctoral Trainee (previously held)
Boston University School of Medicine, Graduate Medical Sciences
Biomedical Research Technologies
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Shi Y, Dincheva-Vogel L, Ayemoba CE, Fung JP, Bergamaschi C, Pavlakis GN, Farzaneh F, Gaensler KML. IL-15/IL-15Ra/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice. Blood Adv. 2018 11 27; 2(22):3177-3192. PMID: 30482760; PMCID: PMC6258921; DOI: 10.1182/bloodadvances.2018019026;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.